Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need.
We have an experienced team that has advanced multiple product candidates in parallel that focus on a range of debilitating diseases with significant unmet medical need. We continue to explore expanding our pipeline in order to develop life-changing medicines for patients who need it most.
We are focused on hiring and retaining a highly skilled team that has extensive experience and specific skill sets relating to the selection, development, and commercialization of transformative therapies. Whether in development, research, manufacturing, technical operations, or general / administrative functions, we depend on a brilliant team to support our mission of building a global, generational company.
Our benefits are competitive, and we offer dynamic career opportunities across our organization fostering a culture that embraces passion and rapid execution.
Location: United States, Massachusetts, Lexington
Employees: 201-500
Founded date: 2015
Investors 2
| Date | Name | Website |
| - | Foresite C... | foresiteca... |
| - | Sofinnova ... | sofinnova.... |
Mentions in press and media 11
| Date | Title | Description | Source |
| 17.07.2023 | Kiniksa Pharmaceuticals to Report Second Quarter 2023 Financ... | /EIN News/ -- HAMILTON, Bermuda, July 17, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Na... | einpresswi... |
| 06.06.2023 | Kiniksa Pharmaceuticals to Present at Goldman Sachs 44th Ann... | /EIN News/ -- HAMILTON, Bermuda, June 06, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Na... | einpresswi... |
| 27.02.2023 | Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Ye... | /EIN News/ -- HAMILTON, Bermuda, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Na... | einpresswi... |
| 31.10.2022 | Kiniksa Pharmaceuticals to Report Third Quarter 2022 Financi... | /EIN News/ -- HAMILTON, Bermuda, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Na... | einpresswi... |
| 03.08.2022 | Kiniksa Pharmaceuticals to Present at 2022 Wedbush PacGrow H... | HAMILTON, Bermuda, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) an... | globenewsw... |
| 18.02.2022 | Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Ye... | HAMILTON, Bermuda, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) an... | globenewsw... |
| 03.01.2022 | Kiniksa Pharmaceuticals to Present at 40th Annual J.P. Morga... | HAMILTON, Bermuda, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) an... | globenewsw... |
| 28.12.2021 | Kiniksa Announces Results from Phase 3 Trial of Mavrilimumab... | HAMILTON, Bermuda, Dec. 28, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“... | globenewsw... |
| 23.11.2021 | Kiniksa Pharmaceuticals to Present at Evercore ISI 4th Annua... | HAMILTON, Bermuda, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) an... | globenewsw... |
| 12.04.2021 | KINIKSA PHARMACEUTICALS, LTD. Kiniksa Announces Positive Re... | – Primary endpoint achieved: the proportion of patients alive and free of mechanical ventilation at ... | marketscre... |
Show more